Top

Published in:

Open Access 01-05-2018 | Original Article

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

Authors: C. Ranieri, S. Di Tommaso, D. C. Loconte, V. Grossi, P. Sanese, R. Bagnulo, F. C. Susca, G. Forte, A. Peserico, A. De Luisi, A. Bartuli, A. Selicorni, D. Melis, M. Lerone, A. D. Praticò, G. Abbadessa, Y. Yu, B. Schwartz, Martino Ruggieri, Cristiano Simone, Nicoletta Resta

Published in: Neurogenetics | Issue 2/2018

Abstract

Postzygotic mutations of the PIK3CA [phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha] gene constitutively activate the PI3K/AKT/mTOR pathway in PIK3CA-related overgrowth spectrum (PROS) patients, causing congenital mosaic tissue overgrowth that even multiple surgeries cannot solve. mTOR inhibitors are empirically tested and given for compassionate use in these patients. PROS patients could be ideal candidates for enrolment in trials with PI3K/AKT pathway inhibitors, considering the “clean” cellular setting in which a unique driver, a PIK3CA mutation, is present. We aimed to assess the effects of blocking the upstream pathway of mTOR on PROS patient-derived cells by using ARQ 092, a potent, selective, allosteric, and experimental orally bioavailable and highly selective AKT-inhibitor with activity and long-term tolerability, currently under clinical development for treatment of cancer and Proteus syndrome. Cell samples (i.e., primary fibroblasts) were derived from cultured tissues obtained from six PROS patients [3 boys, 3 girls; aged 2 to 17 years] whose spectrum of PIK3A-related overgrowth included HHML [hemihyperplasia multiple lipomatosis; n = 1], CLOVES [congenital lipomatosis, overgrowth, vascular malformations, epidermal nevi, spinal/skeletal anomalies, scoliosis; n = 1], and MCAP [megalencephaly capillary malformation syndrome; n = 4]. We performed the following: (a) a deep sequencing assay of PI3K/AKT pathway genes in the six PROS patients’ derived cells to identify the causative mutations and (b) a pathway analysis to assess the phosphorylation status of AKT [Ser473 and Thr308] and its downstream targets [pAKTS1 (Thr246), pRPS6 (Ser235/236), and pRPS6Kβ1 (Ser371)]. The anti-proliferative effect of ARQ 092 was tested and compared to other PI3K/AKT/mTOR inhibitors [i.e., wortmannin, LY249002, and rapamycin] in the six PROS patient-derived cells. Using ARQ 092 to target AKT, a critical node connecting PI3K and mTOR pathways, we observed the following: (1) strong anti-proliferative activity [ARQ 092 at 0.5, 1, and 2.5 μM blunted phosphorylation of AKT and its downstream targets (in the presence or absence of serum) and inhibited proliferation after 72 h; rapamycin at 100 nM did not decrease AKT phosphorylation] and (2) less cytotoxicity as compared to rapamycin and wortmannin. We demonstrated the following: (a) that PROS cells are dependent on AKT; (b) the advantage of inhibiting the pathway immediately downstream of PI3K to circumventing problems depending on multiple classes a PI3K kinases; and (c) that PROS patients benefit from inhibition of AKT rather than mTOR. Clinical development of ARQ 092 in PROS patients is on going in these patients.

Available only for authorised users

Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Parker VE, Blumhorst C, Darling T, Tosi LL, Huson SM, Whitehouse RW, Jakkula E, Grant I, Balasubramanian M, Chandler KE, Fraser JL, Gucev Z, Crow YJ, Brennan LM, Clark R, Sellars EA, Pena LD, Krishnamurty V, Shuen A, Braverman N, Cunningham ML, Sutton VR, Tasic V, Graham JM Jr, Geer J Jr, Henderson A, Semple RK, Biesecker LG (2014) Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am J Med Genet A 164A(7):1713–1733. https://doi.org/10.1002/ajmg.a.36552 CrossRefPubMed

Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG (2015) PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 167A(2):287–295. https://doi.org/10.1002/ajmg.a.36836 CrossRefPubMed

Vahidnezhad H, Youssefian L, Uitto J (2016) Molecular genetics of the PI3K-AKT-mTOR pathway in Genodermatoses: diagnostic implications and treatment opportunities. J Invest Dermatol 136(1):15–23. https://doi.org/10.1038/JID.2015.331 CrossRefPubMed

Vahidnezhad H, Youssefian L, Baghdadi T, Sotoudeh S, Tavassoli A, Zeinali S, Afsharaalam S, Uitto J (2016) Phenotypic heterogeneity in PIK3CA-related overgrowth spectrum. Br J Dermatol 175(4):810–814. https://doi.org/10.1111/bjd.14618 CrossRefPubMed

Ruggieri M, Praticò AD (2015) Mosaic neurocutaneous phenotypes. Semin Pediatr Neurol 22(4):207–233. https://doi.org/10.1016/j.spen.2015.11.001 CrossRefPubMed

Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, Herrera-Garcia JD, Luque-Valenzuela M, Sanchez-Cano D, Lopez-Gutierrez JC, Ruiz-Villaverde R, Tercedor-Sanchez J (2017) CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS). Clin Genet 91(1):14–21. https://doi.org/10.1111/cge.12832 CrossRefPubMed

Raju RR, Hart WR, Magnuson DK, Reid JR, Rogers DG (2002) Genital tract tumors in Proteus syndrome: report of a case of bilateral paraovarian endometrioid cystic tumors of borderline malignancy and review of the literature. Mod Pathol 15(2):172–180. https://doi.org/10.1038/modpathol.3880510 CrossRefPubMed

Vasquez L, Tello M, Maza I, Oscanoa M, Dueñas M, Castro H, Latorre A (2015) Endometrioid Paraovarian borderline cystic tumor in an infant with Proteus syndrome. Case Rep Oncol Med 2015:392576PubMedPubMedCentral

Orloff MS, He X, Peterson C, Chen F, Chen JL, Mester JL, Eng C (2013) Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet 92(1):76–80. https://doi.org/10.1016/j.ajhg.2012.10.021 CrossRefPubMedPubMedCentral

10.

Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovée JV, Rialon KL, Guevara CJ, Alomari AI, Greene AK, Fishman SJ, Kozakewich HP, Maclellan RA, Mulliken JB, Rahbar R, Spencer SA, Trenor CC 3rd, Upton J, Zurakowski D, Perkins JA, Kirsh A, Bennett JT, Dobyns WB, Kurek KC, Warman ML, McCarroll SA, Murillo R (2015) Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr 166(4):1048–1054. https://doi.org/10.1016/j.jpeds.2014.12.069 CrossRefPubMedPubMedCentral

11.

Loconte DC, Grossi V, Bozzao C, Forte G, Bagnulo R, Stella A, Lastella P, Cutrone M, Benedicenti F, Susca FC, Patruno M, Varvara D, Germani A, Chessa L, Laforgia N, Tenconi R, Simone C, Resta N (2015) Molecular and functional characterization of three different postzygotic mutations in PIK3CA-related overgrowth Spectrum (PROS) patients: effects on PI3K/AKT/mTOR signaling and sensitivity to PIK3 inhibitors. PLoS One 10(4):e0123092. https://doi.org/10.1371/journal.pone.0123092 CrossRefPubMedPubMedCentral

12.

Lindhurst MJ, Parker VE, Payne F, Sapp JC, Rudge S, Harris J, Witkowski AM, Zhang Q, Groeneveld MP, Scott CE, Daly A, Huson SM, Tosi LL, Cunningham ML, Darling TN, Geer J, Gucev Z, Sutton VR, Tziotzios C, Dixon AK, Helliwell T, O'Rahilly S, Savage DB, Wakelam MJ, Barroso I, Biesecker LG, Semple RK (2012) Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet 44(8):928–933. https://doi.org/10.1038/ng.2332 CrossRefPubMedPubMedCentral

13.

Takenouchi T, Sakamoto Y, Torii C, Hata K, Kosaki R, Kosaki K (2015) Mosaic overgrowth with fibroadipose hyperplasia due to AKT1 mutation. Am J Med Genet A 167A:287–295

14.

Rios JJ, Paria N, Burns DK, Israel BA, Cornelia R, Wise CA, Ezaki M (2013) Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum Mol Genet 22(3):444–451. https://doi.org/10.1093/hmg/dds440 CrossRefPubMed

15.

Maclellan RA, Luks VL, Vivero MP, Mulliken JB, Zurakowski D, Padwa BL, Warman ML, Greene AK, Kurek KC (2014) PIK3CA activating mutations in facial infiltrating lipomatosis. Plast Reconstr Surg 133(1):12e–19e. https://doi.org/10.1097/01.prs.0000436822.26709.7c CrossRefPubMed

16.

Tajima S, Takanashi Y, Koda K (2015) Enlarging cystic lymphangioma of the mediastinum in an adult: is this a neoplastic lesion related to the recently discovered PIK3CA mutation? Int J Clin Exp Pathol 8(5):5924–5928PubMedPubMedCentral

17.

Yeung KS, Ip JJ, Chow CP, Kuong EY, Tam PK, Chan GC, Chung BH (2017) Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum. Am J Med Genet A 173(4):978–984. https://doi.org/10.1002/ajmg.a.38105 CrossRefPubMed

18.

Hafner C, López-Knowles E, Luis NM, Toll A, Baselga E, Fernández-Casado A, Hernández S, Ribé A, Mentzel T, Stoehr R, Hofstaedter F, Landthaler M, Vogt T, Pujol RM, Hartmann A, Real FX (2007) Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A 104(33):13450–13454. https://doi.org/10.1073/pnas.0705218104 CrossRefPubMedPubMedCentral

19.

van Steensel MAM (2015) Neurocutaneous manifestations of genetic mosaicism. J Pediatr Genet 4(3):144–153. https://doi.org/10.1055/s-0035-1564441 CrossRefPubMedPubMedCentral

20.

Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, Spencer SA, Mulliken JB, Bowen ME, Yamamoto GL, Kozakewich HP, Warman ML (2012) Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 90(6):1108–1115. https://doi.org/10.1016/j.ajhg.2012.05.006 CrossRefPubMedPubMedCentral

21.

Vahidnezhad H, Youssefian L, Uitto J (2016) Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). Exp Dermatol 25(1):17–19. https://doi.org/10.1111/exd.12826 CrossRefPubMed

22.

Rivière JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM, Worthylake T, Sullivan CT, Ward TR, Butler HE, Kramer NA, Albrecht B, Armour CM, Armstrong L, Caluseriu O, Cytrynbaum C, Drolet BA, Innes AM, Lauzon JL, Lin AE, Mancini GM, Meschino WS, Reggin JD, Saggar AK, Lerman-Sagie T, Uyanik G, Weksberg R, Zirn B, Beaulieu CL, Finding of Rare Disease Genes (FORGE) Canada Consortium, Majewski J, Bulman DE, O'Driscoll M, Shendure J, Graham JM Jr, Boycott KM, Dobyns WB (2012) De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 44(8):934–940. https://doi.org/10.1038/ng.2331 CrossRefPubMedPubMedCentral

23.

Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, Scott E, Bafna V, Hill KJ, Collazo A, Funari V, Russ C, Gabriel SB, Mathern GW, Gleeson JG (2012) De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 44(8):941–945. https://doi.org/10.1038/ng.2329 CrossRefPubMedPubMedCentral

24.

Jansen LA, Mirzaa GM, Ishak GE, O'Roak BJ, Hiatt JB, Roden WH, Gunter SA, Christian SL, Collins S, Adams C, Rivière J-B, St-Onge J, Ojemann JG, Shendure J, Hevner RF, Dobyns WB (2015) PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. Brain 138(6):1613–1628. https://doi.org/10.1093/brain/awv045 CrossRefPubMedPubMedCentral

25.

Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, Eklund L, Boon LM, Vikkula M (2015) Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet 97(6):914–921. https://doi.org/10.1016/j.ajhg.2015.11.011 CrossRefPubMedPubMedCentral

26.

Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, Turner J, Cannons JL, Bick D, Blakemore L, Blumhorst C, Brockmann K, Calder P, Cherman N, Deardorff MA, Everman DB, Golas G, Greenstein RM, Kato BM, Keppler-Noreuil KM, Kuznetsov SA, Miyamoto RT, Newman K, Ng D, O'Brien K, Rothenberg S, Schwartzentruber DJ, Singhal V, Tirabosco R, Upton J, Wientroub S, Zackai EH, Hoag K, Whitewood-Neal T, Robey PG, Schwartzberg PL, Darling TN, Tosi LL, Mullikin JC, Biesecker LG (2011) A mosaic activating mutation in AKT1 associated with the Proteus syndrome. New Engl J Med 365(7):611–619. https://doi.org/10.1056/NEJMoa1104017 CrossRefPubMed

27.

Hussain K, Challis B, Rocha N, Payne F, Minic M, Thompson A, Daly A, Scott C, Harris J, Smillie BJ, Savage DB, Ramaswami U, De Lonlay P, O'Rahilly S, Barroso I, Semple RK (2011) An activating mutation of AKT2 and human hypoglycemia. Science 334(6055):474. https://doi.org/10.1126/science.1210878 CrossRefPubMedPubMedCentral

28.

Poduri A, Evrony GD, Cai X, Elhosary PC, Beroukhim R, Lehtinen MK, Hills LB, Heinzen EL, Hill A, Hill RS, Barry BJ, Bourgeois BF, Riviello JJ, Barkovich AJ, Black PM, Ligon KL, Walsh CA (2012) Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74(1):41–48. https://doi.org/10.1016/j.neuron.2012.03.010 CrossRefPubMedPubMedCentral

29.

Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C (1997) Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16(4):333–334. https://doi.org/10.1038/ng0897-333 CrossRefPubMed

30.

Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16(1):64–67. https://doi.org/10.1038/ng0597-64 CrossRefPubMed

31.

Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510. https://doi.org/10.1038/onc.2008.245 CrossRefPubMedPubMedCentral

32.

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501. https://doi.org/10.1038/nrc839 CrossRefPubMed

33.

Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathways in cancer. Nat Rev Drug Discov 8(8):627–644. https://doi.org/10.1038/nrd2926 CrossRefPubMedPubMedCentral

34.

Karakas B, Bachman KE, Park BH (2006) Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94(4):455–459. https://doi.org/10.1038/sj.bjc.6602970 CrossRefPubMedPubMedCentral

35.

Brugge J, Hung MC, Mills GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12(2):104–107. https://doi.org/10.1016/j.ccr.2007.07.014 CrossRefPubMed

36.

Landgraf KE, Pilling C, Falke JJ (2008) Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 47(47):12260–12269. https://doi.org/10.1021/bi801683k CrossRefPubMed

37.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101. https://doi.org/10.1126/science.1106148 CrossRefPubMed

38.

Najafov A, Shpiro N, Alessi DR (2012) AKT is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem J 448(2):285–295. https://doi.org/10.1042/BJ20121287 CrossRefPubMed

39.

Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261–1274. https://doi.org/10.1016/j.cell.2007.06.009 CrossRefPubMedPubMedCentral

40.

Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos DΑ, Libra M, Tsatsakis AM (2016) Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use. Int J Oncol 8:869–885CrossRef

41.

Roy A, Skibo J, Kalume F, Ni J, Rankin S, Lu Y, Dobyns WB, Mills GB, Zhao JJ, Baker SJ, Millen KJ (2015) Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. elife 4:e12703CrossRefPubMedPubMedCentral

42.

Yu Y, Savage RE, Eathiraj S, Meade J, Wick MJ, Hall T, Abbadessa G, Schwartz B (2015) Targeting AKT1-E17K and the PI3K/AKT pathway with an allosteric AKT inhibitor, ARQ 092. PLoS One 10(10):e0140479. https://doi.org/10.1371/journal.pone.0140479 CrossRefPubMedPubMedCentral

43.

Wang Q, Chen X, Hay N (2017) Akt as a target for cancer therapy: more is not always better (lessons from studies in mice). Br J Cancer 19:63 doi: https://doi.org/10.1186/s13058-017-0854-1

44.

Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15(1):7–24. https://doi.org/10.1038/nrc3860 CrossRefPubMedPubMedCentral

45.

Lindhurst MJ, Yourick MR, Yu Y, Savage RE, Ferrari D, Biesecker LG (2015) Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome. Sci Rep 5(1):17162. https://doi.org/10.1038/srep17162 CrossRefPubMedPubMedCentral

46.

Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13(2):140–156. https://doi.org/10.1038/nrd4204 CrossRefPubMedPubMedCentral

Title: In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
Authors: C. Ranieri
S. Di Tommaso
D. C. Loconte
V. Grossi
P. Sanese
R. Bagnulo
F. C. Susca
G. Forte
A. Peserico
A. De Luisi
A. Bartuli
A. Selicorni
D. Melis
M. Lerone
A. D. Praticò
G. Abbadessa
Y. Yu
B. Schwartz
Martino Ruggieri
Cristiano Simone
Nicoletta Resta
Publication date: 01-05-2018
Publisher: Springer Berlin Heidelberg
Published in: Neurogenetics / Issue 2/2018
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI: https://doi.org/10.1007/s10048-018-0540-1

At a glance: The STEP trials

Springer Medicine

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype

Genetic test utilization and diagnostic yield in adult patients with neurological disorders

Phenotypic manifestations of the m.8969G>A variant

The impact of next-generation sequencing on the diagnosis of pediatric-onset hereditary spastic paraplegias: new genotype-phenotype correlations for rare HSP-related genes

WES homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy reveals intronic GDAP1 variant leading to a premature stop codon

Reply to ‘Letter to Editor by Finsterer J and Zarrouk-Mahjoub S: Phenotypic manifestations of the m.8969G>A variant’